New drug duo targets tough breast cancer in small trial
NCT ID NCT07153965
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This phase 2 trial tests a combination of two drugs—Sacituzumab tirumotecan and Tagitanlimab—in 47 people with PD-L1-positive advanced triple-negative breast cancer that has already been treated. The goal is to see if the combo can shrink tumors or slow the disease. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 30000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab tirumotecan (Sac-TMT) plus tagitanlimab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced triple-negative breast cancer that has not responded to prior therapy.
What could go wrong
This is an early-phase, single-arm study with only 47 participants, so results may not be conclusive. The combination may cause significant side effects and may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.